BEDFORD, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Insulet Corporation , the manufacturer and marketer of the OmniPod(R) Insulin Management System, announced today that it has filed a registration statement relating to an underwritten public offering of 4,898,398 shares of its common stock, all of which are being sold by selling stockholders. Insulet has granted the underwriters the right to purchase up to an additional 734,759 shares to cover over-allotments, if any. Insulet will not receive any proceeds from the sale of shares by the selling stockholders.
J.P. Morgan Securities Inc. and Merrill Lynch, Pierce, Fenner & Smith Incorporated will serve as joint book-running managers, and Leerink Swann & Co., Inc., Thomas Weisel Partners LLC and Canaccord Adams Inc. will serve as co-managers for the proposed offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer or sale will be made only by means of a written prospectus forming part of the effective registration statement.
A preliminary prospectus relating to these securities may be obtained by contacting one of the following:
J.P. Morgan Securities Inc., National Statement Processing, Prospectus Library, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245 or by calling (718) 242-8002.
Merrill Lynch, Pierce, Fenner & Smith Incorporated, World Financial Center, 250 Vesey Street, New York, NY 10080 or by calling (212) 449-1000.
About Insulet Corporation
Insulet Corporation is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company’s OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use parts with no tubing and fully- automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. Founded in 2000, Insulet is based in Bedford, MA.
For more information about Insulet Corporation and the OmniPod System, please visit our website at www.insulet.com.
CONTACT: Stephanie Marks for Insulet Corporation, +1-877-763-3471,
ir@insulet.com
Web site: http://www.insulet.com/
